1. Introduction {#s0005}
===============

Prevention of opioid overdose-related mortality has become a key target of public health promotion in the past two decades due to rapid increases in use and misuse of both prescribed and/or illicit opioids ([@bb0005]; [@bb0025]; [@bb0065]). The rate of opioid overdose-related mortality increases up to 4-fold with co-prescribed benzodiazepines, primarily because the risk of respiratory depression, which is independently associated with each medication, is compounded when the two are co-administered ([@bb0055]; [@bb0115]; [@bb0155]). Given this risk, on August 31, 2016, the U.S. Food and Drug Administration (FDA) announced requirements for a "black box" warning. This warning is included in the prescribing information for all benzodiazepine- or opioid-containing products to alert prescribers of the serious risk of respiratory depression and death from opioid-benzodiazepine co-prescription. The warning suggests prescribing this combination only if necessary, for a limited duration, at a limited dose, only if alternative treatment options are unavailable, and with close monitoring ([@bb0160]).

Even before the FDA warning was issued, trends in opioid-benzodiazepine co-prescription may have begun to decline, but evidence on this point is inconsistent. One analysis of office visits made by adults aged ≥20 years for pain-related conditions found that the rate of opioid co-prescription in patients using benzodiazepines, measured per 1000 persons, increased by 86% from 189 in 2005 to 351 in 2010, and declined thereafter to 172 in 2015 ([@bb0070]). However, another study using the same data source and measuring opioid-benzodiazepine co-prescription in adults aged 18--64 years making an office visit for pain-related conditions found a relatively steady rate of increase from 9.8 per 10,000 visits in 1993 to 62.5 per 10,000 visits in 2014 ([@bb0035]).

Whether this difference in findings reflects the inclusion of older adults in the study by Ladapo et al. but not that of Hirschtritt et al. is an important question, because the morbidity and mortality risks associated with opioid-benzodiazepine co-prescription are elevated in patients aged ≥65 years. In one study of emergency visits made for co-prescribed opioid-benzodiazepine from 2005 to 2011, patients aged ≥65 years had the highest predicted risk of hospital admission or death compared with patients in younger age groups ([@bb0150]). Opioid-benzodiazepine combined misuse also increases the risk of suicidal ideation in older adults ([@bb0140]). Because of these risks, the generally limited base of evidence about the prevalence and predictors of opioid-benzodiazepine misuse by older adults has been identified as an important gap in the literature ([@bb0075]), and our more recent search of the literature on medication use by older adults supports this viewpoint ([@bb0035]; [@bb0070]).

In addition to addressing this gap in information about older adults, the present study was conducted to expand the surveillance of high-risk opioid prescribing (HROP) in two ways. First, the study included barbiturates and hypnotics in the definition of HROP because opioid-related respiratory depression risk may be increased by central nervous system depressants other than benzodiazepines ([@bb0120]; [@bb0105]). Second, all opioid-treated patients, rather than only those with pain-related diagnoses, were included in the present study sample to inform prevention initiatives by providing information about population-level prevalence and predictors of HROP. The study examined trends in opioid and HROP over the ten-year period beginning in 2006, comparing rates of use in cohorts of patients aged 18--64 years and ≥65 years. Additionally, the study assessed predictors of HROP in 2014 through the first 8 months of 2016, the 32-month time period preceding the FDA black-box warning.

2. Materials and methods {#s0010}
========================

2.1. Data source {#s0015}
----------------

Study data were obtained from the National Ambulatory Medical Care Survey (NAMCS), a nationally representative assessment of care provided in office visits made to non-federally employed U.S. physicians, which is conducted annually by the National Center for Health Statistics (NCHS). NAMCS data are widely used in published research on use of medications, including controlled substances ([@bb0035]; [@bb0015]; [@bb0020]; [@bb0110]).

Details of the NAMCS sampling strategy and data collection methods are described in detail elsewhere ([@bb0095]). Briefly, the NCHS uses a complex, multistage sampling design that includes stratification by physician specialty, cluster sampling by physician, random selection of one of 52 weeks each year, and random sampling of visits within the chosen week. Prior to 2012, cluster sampling by geographic area was also employed. For each sampled office visit, U.S. Bureau of the Census field representatives abstract data elements from the medical record using an automated laptop-based survey instrument ([@bb0100]).

Data collected by the NCHS include diagnoses (up to three until 2013, up to five beginning in 2014); treatments, services, and laboratory tests ordered or provided at the visit; and prescribed medications that were either initiated or continued by the treating provider. Although up to 30 drugs are currently recorded in NAMCS, the present study is based on the first eight listed drugs through 2011, the maximum recorded in that time frame, and the first ten listed drugs thereafter. Additionally, data collectors record conditions that are clinically important but may not have prompted the extant office visit. Examples include diabetes, hypertension, and hyperlipidemia.

2.2. Design and sample {#s0020}
----------------------

Choice of the design, sample, and analytic covariates for the present study were based on a review of the literature on use of opioids and other controlled substances by older adults. We used a repeated cross-sectional cohort design in which office visits were the unit of analysis. The sampling frame comprised all office visits provided to U.S. adults aged 18 years or older on the visit date during the period from 2006 through the first 8 months of 2016. Cohorts were defined based on age: 18--64 years and ≥65 years. To provide additional information about utilization patterns by age group, especially for older adults, age categories for post hoc analyses of time trends and for logistic regression analyses were based on those of [@bb0035], with added categories representing adults aged 65--74 and ≥75 years. Another post hoc trend analysis examined trends for patients with chronic noncancer pain or substance use disorder because opioid use in these groups has been a target of public health initiatives ([@bb0010]).

2.3. Study measures {#s0025}
-------------------

To identify drugs for study, Multum Lexicon generic drug codes provided by the NCHS were matched to drug names, which were classified into therapy categories for analysis ([Appendix 1](#s0060){ref-type="sec"}). Drug-related measures included the prescribing of at least one opioid at the visit, alone or with a barbiturate, benzodiazepine, or hypnotic (i.e., HROP). Medical conditions and comorbidities were identified using condition/comorbidity indicators and diagnoses, measured as International Classification of Diseases, Ninth Revision (ICD-9) codes in 2014--2015 and ICD-10 codes in 2016 ([Appendix 2](#s0065){ref-type="sec"}).

2.4. Statistical analyses {#s0030}
-------------------------

Use prevalence rates for each drug or drug combination were defined as the number of visits at which the drug was newly prescribed or continued, divided by the total number of visits. HROP prevalence rates were calculated as total number of HROP visits expressed as a proportion of all visits at which an opioid was prescribed. Longitudinal analysis examined these rates over time, grouping data into multiyear time periods as advised by the NCHS to increase statistical reliability, a commonly used technique in analyses of this dataset ([@bb0015]; [@bb0040]; [@bb0090]; [@bb0110]).

For the most recent time period included in the study, 2014 through the first 8 months of 2016, patient characteristics---including sex, cardiovascular risk factors and diagnosed cardiovascular disease, chronic pain, psychiatric conditions, and substance use disorder---were measured as prevalence rates (total number of visits in which the diagnosis or condition was reported, divided by total number of visits). In bivariate analyses of high-risk opioid users, these calculations were performed separately for each of the two age groups. Characteristics included in these analyses were chosen from literature review, specifically based on (a) those reported by Hirschtritt et al. as significant predictors of opioid-benzodiazepine use compared with opioid use alone, such as substance use disorder, anxiety, and depression, plus (b) risk factors (e.g., diabetes, hypertension) and diagnoses for cardiovascular or respiratory diseases, which are often chronically comorbid with substance use disorders ([@bb0170]).

To assess the independent associations of each demographic and clinical characteristic with high-risk opioid use, a binary logistic regression of high-risk opioid use on demographic and clinical predictors was performed. To increase statistical power for this analysis, the list of cardiovascular risk factors was recoded to categories of 1, 2, or ≥3, compared with no (0) risk factors as the reference category. Additionally, predictors that were insignificant in both the work of [@bb0035] and in the bivariate analysis were not included in the logistic regression analysis, with the exception that chronic pain was included because of the focus on patients with this condition in previous work ([@bb0035]; [@bb0070]). The logistic regression analysis was limited to patients without cancer due to the high rate of opioid use within this population.

2.5. Statistical reliability and calculation of nationally representative estimates {#s0035}
-----------------------------------------------------------------------------------

For each office visit record, the NCHS provides (1) a weight that adjusts for the sampling design and nonresponse and (2) sample design weights that reflect the clustered and stratified design. Using these weights, procedures for complex samples produce nationally representative estimates and sampling variance measures that have been adjusted for sampling design. For the present study, the SPSS (IBM SPSS, Armonk, NY) v25.0 complex samples procedure was used. Estimates were assessed for statistical reliability using the standard recommended by the NCHS of ≥30 records and ratio of standard error to the estimate \<30% ([@bb0100]).

3. Results {#s0040}
==========

From 2006 to 2007 to 2014--2016 August, opioid prescribing rates in office visits made by adults increased by 40% (from 9.2% to 12.9%) among those aged 18--64 years and by 54% (from 7.1% to 10.9%) among those aged ≥65 years ([Fig. 1](#f0005){ref-type="fig"}). For both age groups, about one-fifth of visits in which opioids were prescribed in 2006--2007 included a concomitant high-risk drug (barbiturate, benzodiazepine, or hypnotic). Through 2012--2013, both age groups displayed similar patterns of increase in HROP rates, expressed as a proportion of opioid-prescribing visits. In 2014--2016 August, HROP rates continued to increase to 26.6% among those aged 18--64 years, while declining to 21.0% among those aged ≥65 years, resulting in a very slight decline from 24.8% in 2012--2013 to 24.6% in 2014--2016 for adults overall (results for all adults not shown in [Fig. 1](#f0005){ref-type="fig"}).Fig. 1Rates of opioid and high-risk opioid prescribing, ^a^2006--2016, ^6^adults, by age category.^a^Rates represent \>1 prescription newly initiated or continued. Opioid prescribing is calculated as a percentage of all office visits. High-risk opioid prescribing (i.e. opioid+benzodiazepine, barbiturate, or hypnotic) is calculated as a percentage of visits in which ≥1 opioid was initiated or continued. ^b^Through August, prior to the warning regarding co-prescription of opioids with benzodiazepines, which was issued on August 31, 2016.Fig. 1

A post-hoc analysis with separate trends for those aged 50--64 years, 65--74 years, and ≥75 years showed a decline in opioid use by those aged ≥75 years ([Fig. 2](#f0010){ref-type="fig"}, Panel A) and a leveling off of HROP among patients aged 65--74 years who were prescribed opioids, from 22.9% in 2012--2013 to 22.7% in 2014--2016 August ([Fig. 2](#f0010){ref-type="fig"}, Panel B). Among patients aged ≥75 years who were prescribed opioids, trends in HROP fluctuated over time, declining to 18.5% in 2014--2016 August ([Fig. 2](#f0010){ref-type="fig"}, Panel B). Sensitivity analyses of patients with chronic noncancer pain or substance use disorder produced similar results, although the number of older adults with substance use disorder was insufficient for analysis until 2012--2013 ([Appendix 3](#s0070){ref-type="sec"}).Fig. 2Rates of opioid and high-risk opioid prescribing, ^a^2006--2016, ^6^older adults, by age category.^a^Rates represent \>1 prescription newly initiated or continued. Opioid prescribing is calculated as a percentage of all office visits. High-risk opioid prescribing (i.e. opioid+benzodiazepine, barbiturate, or hypnotic) is calculated as a percentage of visits in which ≥1 opioid was initiated or continued. ^b^Through August, prior to the warning regarding co-prescription of opioids with benzodiazepines, which was issued on August 31, 2016.Fig. 2

In 2014--2016 August, approximately 63 million office visits made by US adults resulted in the initiation or continuation of a high-risk opioid combination ([Table 1](#t0005){ref-type="table"}). In these visits, commonly recorded diagnoses or conditions included chronic pain (50%), hypertension (42%), and depression (25%).Table 1Characteristics (%) by age group, patients prescribed ≥1 high-risk opioid combination (opioids+barbiturate, benzodiazepine, or hypnotic), 2014--2016 August[a](#tf0005){ref-type="table-fn"}.Table 1Aged 18--64 yearsAged \>65 yearsAllUnweighted N14165982014Weighted N, annualized46,322,84816,851,25463,174,102Female59.3%59.2%59.3%Race White86.7%86.3%86.6% Nonwhite13.3%NR13.4%Comorbid cardiac risk factors Diabetes^⁎⁎^13.7%26.5%17.1% Hyperlipidemia^⁎⁎^22.7%44.2%28.5% Hypertension^⁎⁎^34.2%63.8%42.1% Obesity12.3%8.7%11.4% Obstructive sleep apnea3.9%6.2%4.5% Tobacco use^⁎⁎^37.7%19.8%32.7%Cancer[b](#tf0010){ref-type="table-fn"}3.0%NR3.5%Cardiovascular disease[c](#tf0015){ref-type="table-fn"} (any)^⁎⁎^7.1%27.5%12.5% Atrial fibrillation/arrhythmia[b](#tf0010){ref-type="table-fn"}^,⁎⁎^NR6.2%2.0% Cerebrovascular diseaseNR2.5%1.8% Coronary artery disease^⁎⁎^4.4%20.0%8.6%Pain (chronic)[b](#tf0010){ref-type="table-fn"}52.4%44.2%50.2%Psychiatric comorbidities Anxiety[b](#tf0010){ref-type="table-fn"}17.8%NR17.0% Depression^⁎^26.8%19.7%24.9%Renal disease[d](#tf0020){ref-type="table-fn"}^,⁎⁎^NR16.3%5.9%Respiratory disease[e](#tf0025){ref-type="table-fn"}11.9%16.7%13.2%Substance use disorder[f](#tf0030){ref-type="table-fn"}^,⁎⁎^13.9%5.0%^\^^11.6% Alcohol (diagnosis or code/recommendation)2.7%\^NR2.4%Substance use disorder[f](#tf0030){ref-type="table-fn"}*or* long-term drug use code with controlled substance^⁎⁎^17.2%7.0%14.4%[^1][^2][^3][^4][^5][^6][^7]

As expected, rates of cardiovascular risk factors were significantly higher for older than younger adults; and 28% of older adults, compared with 7% of younger adults, had a diagnosis of cardiovascular disease. Conversely, younger adults were more likely than older adults to have a diagnosis of chronic pain (52% vs. 44%, respectively), depression (27% vs. 20%), or substance use disorder (14% vs. 5%, respectively), and were much more likely to use tobacco (38% vs. 20%, respectively). Anxiety was also common among younger adults (18%). In bivariate analysis of predictors, these factors were strongly predictive of high-risk opioid use, as were age categories based on the work of [@bb0035] ([Appendix 4](#s0075){ref-type="sec"}).

In the logistic regression analysis, the odds of HROP were multiplied by 3.67 (95% confidence interval \[CI\] = 2.91--4.64) with a diagnosis of chronic pain; by 3.52 (95% CI = 2.29--5.41) with anxiety; and were more than doubled with current tobacco use or substance use disorder ([Table 2](#t0010){ref-type="table"}). Cardiovascular risk factors were also associated with increased odds of HROP, although to a lesser degree. Compared with the reference group of adults aged 35--49 years, odds of HROP were not significantly different among those 50--64 years or 65--74 years, but were significantly lower for those aged 18--34 years (odds ratio = 0.53, 95% CI = 0.38--0.74) and those aged ≥75 years (odds ratio = 0.55, 95% CI = 0.36--0.84).Table 2Predictive model of high-risk opioid prescribing, patients without cancer, 2014--2016 August[a](#tf0035){ref-type="table-fn"}.Table 2Exponentiated beta (odds ratio)95% Confidence interval lower limit95% Confidence interval upper limitAge (years) 18--34**0**.**5280**.**3780**.**738** 35 to 49RefRefRef 50 to 64[b](#tf0040){ref-type="table-fn"}1.0600.8241.364 65 to 74[b](#tf0040){ref-type="table-fn"}0.8410.6021.173 75 or older[b](#tf0040){ref-type="table-fn"}**0**.**5520**.**3600**.**844**Anxiety[c](#tf0045){ref-type="table-fn"}**3**.**5212**.**2905**.**412**Depression[b](#tf0040){ref-type="table-fn"}, [c](#tf0045){ref-type="table-fn"}**1**.**7651**.**2542**.**486**Chronic pain[c](#tf0045){ref-type="table-fn"}**3**.**6732**.**9064**.**642**Current tobacco user[c](#tf0045){ref-type="table-fn"}**2**.**2661**.**7942**.**861**Substance use disorder[c](#tf0045){ref-type="table-fn"}, [d](#tf0050){ref-type="table-fn"}**2**.**3241**.**6263**.**323**Comorbid cardiac risk factors[e](#tf0055){ref-type="table-fn"} NoneRefRefRef One[b](#tf0040){ref-type="table-fn"}**1**.**6001**.**2062**.**122** Two[b](#tf0040){ref-type="table-fn"}**1**.**4411**.**0491**.**978** Three or more[b](#tf0040){ref-type="table-fn"}**1**.**7891**.**1942**.**683**[^8][^9][^10][^11][^12][^13][^14]

4. Discussion {#s0045}
=============

In physician office visits made by patients aged ≥65 years, the rate of HROP, which had increased steadily over time from 2006--2007 to 2012--2013, began to decline in 2014--2016 August, primarily because of changes occurring among patients aged ≥75 years and a leveling of the HROP rate among those aged 65--74 years. Since previous research has found a strong association between use of high-risk opioid combinations and high direct and indirect costs, the decreased rate of HROP may translate to improved patient outcomes, decreased costs, and prevention of opioid-overdose related mortality ([@bb0130]; [@bb0060]).

Although a positive finding because of the elevated risk of respiratory depression in older adults, this result is surprising because our study period preceded the issuance of the new FDA guidance on opioid-benzodiazepine co-prescription. The decline in prescribing rates may have been due to several states implementing more stringent requirements for opioid prescriptions prior to 2016. It is also possible that concern about potential opioid-related risks for the "older-older" has increased ([@bb0050]). Our findings are consistent with those of a previous study that reported reduced high-dose opioid use with age ≥75 years ([@bb0085]), perhaps because known opioid-related risks, such as cardiovascular events or fractures ([@bb0135]; [@bb0145]) are highly prevalent and clinically serious in this age group ([@bb0050]).

In contrast to the findings for older adults, the rate of HROP in patients aged 18--64 years continued to increase in 2014--2016 August. The rate of HROP was multiplied \>3-fold with diagnoses of either chronic pain or anxiety, and doubled with a diagnosis of tobacco or substance use disorder. The continued increase of HROP overlaid with these diagnoses may result in unintended harm, such as increased risk of opioid-overdose related mortality.

Among all study patients, there was a slight decline in HROP from 2012--2013 to 2014--2016. This finding aligns with that of [@bb0070], who found an overall reduction in HROP prevalence over time. This reduction was not apparent in the study by [@bb0035], likely due to the exclusion of patients aged ≥65 years from their sample. Despite the present study\'s finding of improvement in HROP rates among patients aged ≥65 years, it should be noted that rates for both age groups remain elevated above those from 2006 to 2007. Additionally, despite the decline in HROP rates, rates of opioid prescribing overall continued to increase among older adults from 2012--2013 to 2014--2016 August, highlighting the importance of public health prevention strategies for opioid use reduction. In concert with the recommendations of the FDA, the Centers for Disease Control and Prevention (CDC) released Guidelines for Prescribing Opioids for Chronic Pain in 2016 that suggest non-pharmacological and non-opioid treatment modalities when managing chronic pain ([@bb0160]; [@bb0010]). As interest in the risks associated with increased controlled substance use and misuse by older adults continues to grow ([@bb0030]; [@bb0045]; [@bb0080]), continued monitoring of trends in HROP in this age group is warranted. Additional research to clarify sociocultural predictors of high-risk drug use, such as family history, criminality, or socioeconomic status, may be helpful to providers who wish to identify older adults who are at elevated risk ([@bb0125]; [@bb0165]).

4.1. Limitations {#s0050}
----------------

Several limitations of the study should be noted. First, the NAMCS does not measure medication strength, prescribed duration or dosage, or patient adherence. Second, each NAMCS record represents a single physician office visit. Other than the medical condition codes (e.g., hypertension, diabetes), the NAMCS record does not provide information on patient history. Third, although the NAMCS record does include medications prescribed by another physician and continued by the sampled physician, it does not capture illicit drugs, prescriptions intentionally concealed by patients (e.g., in "doctor shopping"), or medication that was discontinued in the sampled office visit. Fourth, the study sample represents care delivered in physician office visits, not in emergency departments or inpatient hospital settings.

5. Conclusion {#s0055}
=============

While prescribing rates of high-risk opioid use declined in older adults prior to the FDA Black Box Warning regarding opioid-benzodiazepine co-prescription, these rates continued to trend upwards through the first 8 months of 2016 in adults aged 18--64 years. Future studies are needed to assess the impact of the FDA Black Box Warning and CDC Chronic Pain Guideline from 2016 on the rates of HROP.

Declaration of Competing Interest
=================================

The authors declare there is no conflict of interest.

Appendix 1 {#s0060}
==========

Appendix 1Unweighted counts of drugs by therapy class, office visits made by adults, all years and 2014--2016 August[a](#tf0060){ref-type="table-fn"}.Appendix 12006--20162014--2016Barbiturates[b](#tf0065){ref-type="table-fn"}1521376 Butalbital1292337 Mephobarbital31 Phenobarbital23038Benzodiazepines[b](#tf0065){ref-type="table-fn"}23,7715683 Alprazolam82402054 Chlordiazepoxide33176 Clobazam1611 Clonazepam54271253 Clorazepate18619 Diazepam2912757 Estazolam3811 Flurazepam7513 Lorazepam56251334 Midazolam466128 Oxazepam9517 Temazepam1270243 Triazolam14819Opioids[b](#tf0065){ref-type="table-fn"}34,6888353 Buprenorphine1125339 Butorphanol393 Codeine2438676 Dihydrocodeine51 Fentanyl1224296 Hydrocodone15,9393722 Hydromorphone662160 Mepiridine27238 Methadone780114 Morphine1226280 Nalbuphine370 Opium153 Oxycodone74152031 Oxymorphone12441 Pentazocine254 Propoxyphene127013 Tapentadol10531 Tramadol (became a controlled substance in July 2014)58781570Z hypnotics/other hypnotics[b](#tf0065){ref-type="table-fn"}73711476 Eszopiclone864129 Sodium oxybate143 Suvorexant66 Zaleplon15628 Zolpidem63941319[^15][^16]

Appendix 2 {#s0065}
==========

Appendix 2Medical claims codes for diagnoses.Appendix 2DiagnosisICD-9 codesICD-10 codesAbuse/addiction or condition codes as shown in table shell; note that these codes did not become available until 2014.291 Alcohol-induced mental disorders\
292 Drug-induced mental disorders\
303.xx Alcohol dependence syndrome\
304.xx Drug dependence\
305.xx Nondependent abuse of drugs\
965.0 Poisoning by opiates and related narcotics\
967 Poisoning by sedatives and hypnotics\
969.1, 969.2, 969.4, 969.5, 969.6, 969.7 Poisoning by tranquilizers, hallucinogens, or psychostimulants\
970 Poisoning by central nervous system stimulants\
E850.0 Accidental poisoning by heroin\
E850.1 Accidental poisoning by methadone\
E850.2 Accidental poisoning by other opiates and related\
narcotics\
E851 Accidental poisoning by barbiturates\
E852 Accidental poisoning by other sedatives and hypnotics\
E853 Accidental poisoning by tranquilizers\
E854.1 Accidental poisoning by psychodysleptics\
\[hallucinogens\]\
E854.2 Accidental poisoning by psychostimulants\
E854.3 Accidental poisoning by central nervous system stimulantsF10 Alcohol related disorders\
F11 Opioid related disorders\
F12 Cannabis related disorders\
F13 Sedative, hypnotic, or anxiolytic related disorders\
F14 Cocaine related disorders\
F15 Other stimulant related disorders\
F16 Hallucinogen related disorders\
F18 Inhalant related disorders\
F19 Other psychoactive substance related disorders\
T40 Poisoning by and adverse effects of narcotics and psychodysleptics (excluding codes for underdosing)\
T42.3x, T42.4x, T42.6x, T42.7x poisoning by and adverse effects of barbiturates, benzodiazepines, other/unspecified antiepileptic and sedative-hypnotic drugs (excluding codes for underdosing)\
T43.6x Poisoning by and adverse effects of psychostimulants (excluding codes for underdosing)\
Underdosing is indicated by a code of "6" in the sixth position.\
K70 Alcoholic liver diseaseAngina413 Angina pectorisI20 Angina pectorisAnxiety300 Anxiety, dissociative and somatoform disordersF40 Phobic anxiety disorders\
F41 Other anxiety disorders\
F42 Obsessive compulsive disorder\
F44 Dissociative and conversion disorders\
F45 Somatoform disordersArrhythmia426 Conduction disorders\
427 Cardiac dysrhythmias\
V45.0 Cardiac device in situ; unspecified, pacemaker, automatic implantable defibrillator, or otherI44 Atrioventricular and left bundle-branch block\
I45 Other conduction disorders\
I48 Atrial fibrillation and flutter\
I49 Other cardiac arrhythmias\
Z95.0 Presence of cardiac pacemaker\
Z95.81 Presence of defibrillator, heart assist device, artificial heart, cardiac implantCancer140--149 Malignant neoplasm of lip, oral cavity, and pharynx\
150--159 Malignant neoplasm of digestive organs and peritoneum\
160--165 Malignant neoplasm of respiratory and intrathoracic organs\
170 Malignant neoplasm of bone and articular cartilage\
171 Malignant neoplasm of connective and other soft tissue\
172 Malignant melanoma of skin\
174 Malignant neoplasm of female breast\
175 Malignant neoplasm of male breast\
176 Kaposi\'s sarcoma\
179--189 Malignant neoplasm of genitourinary organs\
190--199 Malignant neoplasm of other and unspecified sites\
200--209 Malignant neoplasm of lymphatic and hematopoietic tissueC00-C14 Malignant neoplasms of lip, oral cavity and pharynx\
C15-C26 Malignant neoplasms of digestive organs\
C30-C39 Malignant neoplasms of respiratory and intrathoracic organs\
C40-C41 Malignant neoplasms of bone and articular cartilage\
C43-C44 Melanoma and other malignant neoplasms of skin\
C45-C49 Malignant neoplasms of mesothelial and soft tissue\
C50-C50 Malignant neoplasms of breast\
C51-C58 Malignant neoplasms of female genital organs\
C60-C63 Malignant neoplasms of male genital organs\
C64-C68 Malignant neoplasms of urinary tract\
C69-C72 Malignant neoplasms of eye, brain and other parts of central nervous system\
C73-C75 Malignant neoplasms of thyroid and other endocrine glands\
C76-C80 Malignant neoplasms of ill-defined, other secondary and unspecified sites\
C7A-C7A Malignant neuroendocrine tumors\
C7B-C7B Secondary neuroendocrine tumors\
C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissueCardiomegaly (LVH)429.3 CardiomegalyI51.7 CardiomegalyCardiomyopathy425 CardiomyopathyI42 Cardiomyopathy\
I43 Cardiomyopathy in diseases classified elsewhereCongenital heart anomalies745 Bulbus cordis anomalies and anomalies of cardiac septal closure\
746 Other congenital anomalies of heart\
747 Other congenital anomalies of circulatory systemQ20 Congenital malformations of cardiac chambers and connections\
Q21 Congenital malformations of cardiac septa\
Q22 Congenital malformations of pulmonary and tricuspid valves\
Q23 Congenital malformations of aortic and mitral valves\
Q24 Other congenital malformations of heart\
Q25 Congenital malformations of great arteries\
Q26 Congenital malformations of great veins\
Q27 Other congenital malformations of peripheral vascular system\
Q28 Other congenital malformations of circulatory systemHepatic impairment070 Viral hepatitis\
570 Acute and subacute necrosis of liver\
571 Chronic liver disease and cirrhosis\
572 Liver abscess and sequelae of chronic liver disease\
573 Other disorders of liverB15 Acute hepatitis A\
B16 Acute hepatitis B\
B17 Other acute viral hepatitis\
B18 Chronic viral hepatitis\
B19 Unspecified viral hepatitis\
K70 Alcoholic liver disease\
K71 Toxic liver disease\
K72 Hepatic failure, not elsewhere classified\
K73 Chronic hepatitis, not elsewhere classified\
K74 Fibrosis and cirrhosis of liver\
K75 Other inflammatory liver diseases\
K76 Other diseases of liver\
K77 Liver disorders in diseases classified elsewhereHypertensive heart disease402 Hypertensive heart disease\
404 Hypertensive heart and chronic kidney diseaseI11 Hypertensive heart disease\
I13 Hypertensive heart and chronic kidney diseaseLong-term drug useV58.69 Long-term (current) use of other medicationsZ79.891 Long-term use of opiate analgesic"Old" MI411.0 Postmyocardial infarction syndrome\
412 Old myocardial infarctionI24.1 Dressler\'s syndrome\
I25.2 Old myocardial infarction"Old" stentV45.81 Aortocoronary bypass status\
V45.82 PTCA statusZ95.1 Presence of aortocoronary bypass graft\
Z95.5 Presence of coronary angioplasty implant and graft\
Z98.6 Angioplasty statusPain (chronic)250.6x Diabetes with neurological manifestations\
338.2x Chronic pain\
338.4x Chronic pain syndrome\
353 Nerve root and plexus disorders\
354 Mononeuritis of upper limb and mononeuritis multiplex\
355 Mononeuritis of lower limb and unspecified site\
356 Hereditary and idiopathic peripheral neuropathy\
357 Inflammatory and toxic neuropathy\
707 Chronic ulcer of skin\
710.xx-719.xx Arthropathies and related disorders\
720.xx-724.xx Dorsopathies\
725.xx-729.xx Rheumatism, excluding the back\
730.xx-739.xx Osteopathies, chondropathies, and acquired musculoskeletal deformities\
V66.7 Encounter for palliative careE08.4 Diabetes mellitus due to underlying condition with neurological complications\
E10.4 Type 1 diabetes mellitus with neurological complications\
E11.4 Type 2 diabetes mellitus with neurological complications\
E13.4 Other specified diabetes mellitus with neurological complications\
G89.2 Chronic pain, not elsewhere classified\
G89.4 Chronic pain syndrome\
G50-G59 Nerve, nerve root and plexus disorders\
G60-G65 Polyneuropathies and other disorders of the peripheral nervous system\
G89 Pain, not elsewhere classified\
L89 Pressure ulcer\
M00-M02 Infectious arthropathies\
M04-M04 Autoinflammatory syndromes\
M05-M14 Inflammatory polyarthropathies\
M15-M19 Osteoarthritis\
M20-M25 Other joint disorders\
M30-M36 Systemic connective tissue disorders\
M40-M43 Deforming dorsopathies\
M45-M49 Spondylopathies\
M50-M54 Other dorsopathies\
M60-M63 Disorders of muscles\
M65-M67 Disorders of synovium and tendon\
M70-M79 Other soft tissue disorders\
M80-M85 Disorders of bone density and structure\
M86-M90 Other osteopathies\
M91-M95 Chondropathies and other disorders of musculoskeletal system\
M96-M97 Postoperative complications and periprosthetic fracture\
Z51.5 Encounter for palliative carePeripheral arterial disease443.9 Peripheral artery disease, unspecifiedI73.9 Peripheral vascular disease, unspecifiedRespiratory disease (chronic) or condition codes as shown in table shell277.0 Cystic fibrosis\
491 Chronic bronchitis\
492 Emphysema\
494 Bronchiectasis\
495 Extrinsic allergic alveolitis\
496 Chronic airway obstruction, not elsewhere classifiedE84 Cystic fibrosis\
J41 Simple and mucopurulent chronic bronchitis\
J42 Unspecified chronic bronchitis\
J43 Emphysema\
J44 Other chronic obstructive pulmonary disease\
J47 BronchiectasisValvular disorders397.0 Diseases of tricuspid valve\
424.0 Mitral valve disorders\
424.1 Aortic valve disorders\
424.2 Tricuspid valve disorders, specified as nonrheumatic\
424.3 Pulmonary valve disorders\
424.9 Endocarditis valve unspecifiedI34 Nonrheumatic mitral valve disorders\
I35 Nonrheumatic aortic valve disorders\
I36 Nonrheumatic tricuspid valve disorders\
I37 Nonrheumatic pulmonary valve disorders\
I38 Endocarditis, valve unspecified\
I39 Endocarditis and heart valve disorders in diseases classified elsewhere

Appendix 3 {#s0070}
==========

Appendix 3Rates of opioid and high-risk opioid prescribing,^a^ 2006--2016,^6^ adults diagnosed with chronic noncancer pain or substance use disorder, by age category.Appendix 3

Appendix 4 {#s0075}
==========

Appendix 4Rate of high-risk combination (opioids+barbiturate, benzodiazepine, or hypnotic) use by sample subgroups, patients without cancer, 2014--2016 August[a](#tf0070){ref-type="table-fn"}.Appendix 4CharacteristicRate[b](#tf0075){ref-type="table-fn"}Sex Female2.9 Male3.1Race White3.2 Nonwhite2.3Age group (years)^⁎⁎^ 18 to 341.7 35 to 493.7 50 to 644.1 65 to 742.7 75 or older1.8Comorbid cardiac risk factors^⁎⁎^ (sum of condition codes for diabetes, hyperlipidemia, hypertension, obesity, sleep apnea, max = 5, truncated at 3 or more) None2.4 One3.9 Two3.2 Three or more3.8 Individual comorbidities Diabetes3.2 Hyperlipidemia^⁎^3.7 Hypertension^⁎⁎^3.7 Obesity^⁎^3.8 Obstructive sleep apnea3.9 Tobacco use^⁎⁎^7.4Cardiovascular disease[c](#tf0080){ref-type="table-fn"}, [d](#tf0085){ref-type="table-fn"} (any)3.1 Cerebrovascular disease2.6 Congestive heart failure2.3 Coronary artery disease3.5Other diagnoses and conditionsPain (chronic)[d](#tf0085){ref-type="table-fn"}^,⁎⁎^7.2Psychiatric comorbidities Anxiety[d](#tf0085){ref-type="table-fn"}^,\ ⁎⁎^10.4 Depression^⁎⁎^6.4Respiratory disease[d](#tf0085){ref-type="table-fn"}, [e](#tf0090){ref-type="table-fn"}^⁎⁎^4.2Substance use disorder[d](#tf0085){ref-type="table-fn"}, [f](#tf0095){ref-type="table-fn"}^⁎⁎^9.1 Alcohol (dx or code/recommendation)^⁎⁎^5.8Substance use disorder *or* long-term drug use code with controlled substance[d](#tf0085){ref-type="table-fn"}, [f](#tf0095){ref-type="table-fn"}^⁎⁎^10.6[^17][^18][^19][^20][^21][^22][^23]

[^1]: BMI = body mass index; COPD = chronic obstructive pulmonary disease; ICD = international classification of diseases; kg = kilograms; m^2^ = body surface area in squared meters; MI = myocardial infarction; NEC = not elsewhere classified; NR = not statistically reliable (standard error exceeds 30% of the estimate). Pearson chi-square test ^⁎^*P* \< 0.05; ^⁎⁎^*P* \< 0.01. ^\^^Indicates that *N* ≥ 20, *N* \< 30, and ratio of standard error to the estimate meets standards for statistical reliability.

[^2]: Through August 2016, prior to the US Food and Drug Administration black-box warning.

[^3]: Coded by diagnosis (ICD-9 in 2014--2015, ICD-10 in 2016); see codes in [Appendix 2](#s0065){ref-type="sec"}. Hepatic impairment estimates are not shown because they did not meet statistical reliability standards.

[^4]: Condition code of coronary artery disease, cerebrovascular disease, or congestive heart failure, or diagnosis of angina, atrial fibrillation/arrhythmia, cardiomegaly, cardiomyopathy, hypertensive heart disease, "old" (history) MI, or peripheral arterial disease. ICD codes in [Appendix 2](#s0065){ref-type="sec"}.

[^5]: Condition code for chronic kidney disease or end-stage renal disease.

[^6]: Condition code for asthma or condition code for COPD or any of the following: cystic fibrosis, chronic bronchitis, emphysema, bronchiectasis, extrinsic allergic alveolitis, chronic airway obstruction NEC; see ICD codes in [Appendix 2](#s0065){ref-type="sec"}.

[^7]: Condition code for substance abuse or alcohol abuse, or provided/recommended education on substance abuse or alcohol abuse, or reason for visit is drug- or alcohol-related, or any diagnosis for addiction/abuse of alcohol, opioids, hypnotics/anxiolytics, stimulants, or other/unspecified substances; see codes in [Appendix 2](#s0065){ref-type="sec"}.

[^8]: N of cases = 53,928 unweighted; Nagelkerke R square = 0.140; C-statistic = 0.719.

[^9]: Bold font denotes statistical significance.

[^10]: Through August 2016, prior to the US Food and Drug Administration black-box warning.

[^11]: Relative standard error \>30%; result should be interpreted cautiously.

[^12]: For diagnoses and medical conditions, reference category includes those without the disorder shown in the row label.

[^13]: Condition code for substance abuse or alcohol abuse, or provided/recommended education on substance abuse or alcohol abuse, or reason for visit is drug- or alcohol-related, or any diagnosis for addiction/abuse of alcohol, opioids, hypnotics/anxiolytics, stimulants, or other/unspecified substances; or code for long-term drug use in patients with a controlled substance prescription; see codes in [Appendix 2](#s0065){ref-type="sec"}.

[^14]: Diabetes, hyperlipidemia, hypertension, obesity, and obstructive sleep apnea.

[^15]: Across all drugs prescribed in the visit; 8 drugs maximum through 2011 and 10 drugs maximum thereafter. Measured through August 2016, prior to the US Food and Drug Administration black-box warning.

[^16]: Indicates use of one or more of the drugs shown in the rows below. Individual drug counts may not sum to therapy class total because patients could use more than one drug.

[^17]: BMI = body mass index; COPD = chronic obstructive pulmonary disease; ICD = international classification of diseases; kg = kilograms; m^2^ = body surface area in squared meters; MI = myocardial infarction; NEC = not elsewhere classified; NR = not statistically reliable (standard error exceeds 30% of the estimate). Pearson chi-square test ^⁎^*P* \< 0.05; ^⁎⁎^*P* \< 0.01. ^\^^Indicates that N ≥ 20, *N* \< 30, and ratio of standard error to the estimate meets standards for statistical reliability.

[^18]: Through August 2016, prior to U.S. Food and Drug Administration black-box warning.

[^19]: Number of those in subgroup with high-risk opioid use, divided by total number in subgroup.

[^20]: Condition code of coronary artery disease, cerebrovascular disease, or congestive heart failure, or diagnosis of angina, atrial fibrillation/arrhythmia, cardiomegaly, cardiomyopathy, hypertensive heart disease, "old" (history) MI, or peripheral arterial disease.

[^21]: ICD codes in [Appendix 2](#s0065){ref-type="sec"}.

[^22]: Condition code for asthma or condition code for COPD or any of the following: cystic fibrosis, chronic bronchitis, emphysema, bronchiectasis, extrinsic allergic alveolitis, chronic airway obstruction NEC.

[^23]: Condition code for substance abuse or alcohol abuse, or provided/recommended education on substance abuse or alcohol abuse, or reason for visit is drug- or alcohol-related, or any diagnosis for addiction/abuse of alcohol, opioids, hypnotics/anxiolytics, stimulants, or other/unspecified substances.
